title: Effects of vitamin E ingestion on plasma and urinary risk factors for calcium oxalate urolithiasis in two population groups having different stone-risk profiles: evidence of different physiological handling mechanisms.
abstract: It has been demonstrated that vitamin E supplementation reduces calciuria and oxaluria and that it may also prevent oxalate-mediated peroxidative injury, all of which reduce the risk of calcium oxalate urolithiasis. In view of the significant difference in stone occurrence in black (B) and white (W) South Africans, we undertook to investigate the effects of vitamin E supplementation in subjects from these two groups. Five healthy males from each group ingested one capsule (400 IU) of vitamin E daily for 60 days. Blood and 24 h urine samples were collected at baseline and on day 60; 24 h dietary questionnaires were simultaneously completed. Urine composition was determined by routine analyses. Urinary and plasma TBARS were determined using a commercially available assay kit while plasma vitamin E was determined by reverse phase HPLC. Plasma vitamin E increased significantly in W but not in B. Urinary and plasma TBARS did not increase in either group. Urinary citrate increased significantly in both groups but the percentage increase in W (169%) was greater than that in B (82%). No other urinary parameter changed significantly. The increase in plasma vitamin E in W but not in B suggests either that the mechanism by which it is packaged into chylomicrons, which are secreted into the systemic circulation, is suppressed in the latter group or that it is differentially absorbed in the two groups. Similarly, to explain the greater increase in citraturia in W compared to B, we speculate that inhibition of lipogenesis of arachidonic acid by vitamin E, ultimately leading to an increase in citraturia, occurs to a lesser extent in B than in W.
authors.affiliation: Department of Chemistry, University of Cape Town, Rondebosch 7700, South Africa.
authors.forename: Takalani
authors.initials: T
authors.lastname: Theka
authors.forename: Allen
authors.initials: A
authors.lastname: Rodgers
authors.forename: Sonja
authors.initials: S
authors.lastname: Lewandowski
authors.forename: Dawn
authors.initials: D
authors.lastname: Webber
authors.forename: Shameez
authors.initials: S
authors.lastname: Allie-Hamdulay
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D044383:Black People; D002129:Calcium Oxalate / Q000378:metabolism*; D002914:Chylomicrons / Q000378:metabolism; D002951:Citrates / Q000378:metabolism; D019587:Dietary Supplements; D006801:Humans; D008297:Male; D012307:Risk Factors; D013019:South Africa; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D052878:Urolithiasis / Q000453:epidemiology* / Q000208:ethnology* / Q000378:metabolism; D014810:Vitamin E / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D044465:White People; D055815:Young Adult; D024502:alpha-Tocopherol / Q000378:metabolism
chemical_list: D002914:Chylomicrons; D002951:Citrates; D017392:Thiobarbituric Acid Reactive Substances; D014810:Vitamin E; D002129:Calcium Oxalate; D024502:alpha-Tocopherol